Latest news, press releases, and SEC filings for Maia Biotechnology Inc (MAIA) https://caymanjournal.com/stock/MAIA en-us Copyright 2026, Cayman Journal editorial@caymanjournal.com (Editorial Team) webmaster@caymanjournal.com (Web Master) Mon, 27 Apr 2026 20:27:41 GMT 60 https://caymanjournal.com/logo.png https://caymanjournal.com 144 144 # 🧾 What This Document Is This is the **Annual Report to Shareholders (ARS)** for MAIA Biotechnology, Inc. Think of it as a company's "year-in-review" magazine, designed for investors. It’s different from the more technical 10-K filing—it’s shorter, more visual, and focuses on telling the company' https://caymanjournal.com/stock/MAIA/sec-filing/0001493152-26-015458 https://caymanjournal.com/stock/MAIA/sec-filing/0001493152-26-015458 Tue, 07 Apr 2026 00:00:00 GMT SEC Filing # 🧾 What This Document Is — A Roadmap for the Annual Vote This is a **Definitive Proxy Statement (DEF 14A)**. Think of it as the official rulebook and information packet for MAIA Biotechnology's upcoming annual shareholder meeting. The company is required to send this to shareholders so they can m https://caymanjournal.com/stock/MAIA/sec-filing/0001140361-26-013499 https://caymanjournal.com/stock/MAIA/sec-filing/0001140361-26-013499 Tue, 07 Apr 2026 00:00:00 GMT SEC Filing # 🧾 What This Document Is This is a **press release** (filed as an Exhibit to an 8-K) from MAIA Biotechnology. The company is sharing exciting early results from a clinical trial of its cancer drug. They presented this data at a major medical conference in Copenhagen on March 27, 2026. 👉 **Why it https://caymanjournal.com/stock/MAIA/sec-filing/0001493152-26-013879 https://caymanjournal.com/stock/MAIA/sec-filing/0001493152-26-013879 Tue, 31 Mar 2026 00:00:00 GMT SEC Filing